This disclosure relates to methods of treating ocular diseases using polyamine analogs, particularly conformationally restricted polyamine analogs. The ocular diseases to be treated include a variety of ophthalmic disorders characterized by angiogenesis and/or neovascularization, including macular degeneration. Both wet macular degeneration and dry macular degeneration can be treated using the methods of the invention. The invention also provides ophthalmic formulations, including sustained release formulations and sustained release devices.